Evidence map›Paper›PMID 26823863›Full record

ArticleInternational journal of clinical and experimental pathology2015

Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma.

Pingping Yan, Miaojuan Xia, Fei Gao, Guanxiu Tang, Hui Zeng, Shuo Yang, Hongmei Zhou, Dan Ding, Lina Gong

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 8 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 8 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Bioscience reports · 2018
    Pooled it
  6. [Association between miR-146a single nucleotide polymorphism and genetic susceptibility to hepatocellular carcinoma: a meta-analysis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Pooled it
  7. Pooled it
  8. Effect ofTechnology in cancer research & treatment
    Pooled it
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Investigation ofAmerican journal of translational research · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pingping YanDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Miaojuan XiaDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Fei GaoHenan Provincial Hospital Number 7 Weiwu Road, Zhengzhou, Henan 450003, China.
Guanxiu TangDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Hui ZengDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Shuo YangDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Hongmei ZhouDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Dan DingDepartment of Geriatrics, The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Lina GongDepartment of Neurology of The Third Xiangya Hospital, Central South University 138 Tongzipo Road, Changsha, Hunan 410013, China.
Central South University · CNHenan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a case-control study to evaluate the association of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) polymorphisms with the risk of hepatocellular carcinoma. A total of 274 patients with HCC were collected between January 2013 and December 2014. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was taken to determine the polymorphism of miR-146a C>G, miR-149 T>C, miR-196a2 T>C and miR-499 T>C. By comparing with control groups, patients with HCC were more likely to be males (OR=2.01, 95% CI=1.38-2.95), have older age (OR=1.52, 95% CI=1.09-2.13), have a history of alcohol drinking (OR=2.09, 95% CI=1.49-2.93), and be infected with HBV (OR=32.98, 95% CI=19.70-55.46) and HCV (OR=56.26, 95% CI=23.28-152.98) infection. By conditional regression analysis, individuals carrying the TC and CC genotypes of miR-196a2 T>C were found to be associated with an elevated risk of HCC compared to the TT genotype, and the adjusted odds ratio were 1.50 (1.03-2.17) and 2.86 (1.60-5.16), respectively. Moreover, the TC+CC genotype was correlated with an increased risk of HCC (OR=1.69, 95% CI=1.19-2.41) compared to the wide-type genotype. In conclusion, our results suggested that miR-196a2 T>C polymorphism is associated with HCC risk in Chinese population.

Indexed as

AdultAgedAsian PeopleCarcinoma, HepatocellularCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansLiver NeoplasmsMaleMicroRNAsMiddle AgedPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPolymorphism, Single NucleotideMicroRNAsMIRN146 microRNA, humanMIRN149 microRNA, humanMIRN196 microRNA, humanMIRN499 microRNA, humanhepatocellular carcinomaMiR-146a C>GmiR-149 T>CmiR-196a2 T>CmiR-499 T>Cpolymorphism

Identifiers

PMID26823863
PMCPMC4713649
OpenAlexW2464607500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.